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A new lead to nLRP3 inhibition
The discovery of a small molecule inhibitor that targets the inflammasome sensor NLRP3 offers a new path for the development 
of selective inflammasome blockers with potential therapeutic benefit in a wide range of human diseases (in this issue, see 
Jiang et al., https ://doi .org /10 .1084 /jem .20171419).
Inflammasomes are cytosolic multi-pro-
tein complexes that form in response 
to diverse cellular insults to promote 
proximity-induced autoprocessing of 
caspase-1 (Lamkanfi and Dixit, 2014). 
Each complex is assembled by sensor 
proteins that respond to particular patho-
genic conditions (see figure). Pyrin/
TRIM20 is a member of the tripartite 
motif (TRIM) family that assembles 
an inflammasome in myeloid cells that 
have been infected with Burkholderia 
cenocepacia, Clostridium difficile, and 
various other pathogens that produce 
RhoA GTPase–inactivating toxins. 
AIM2 (absent in melanoma 2) of the 
HIN200/AIM2-like receptor (ALR) 
family builds an inflammasome in my-
eloid and intestinal epithelial cells when 
it detects viral, bacterial, and host-de-
rived double-stranded DNA (dsDNA) 
in the cytosol. Distinct inflammasomes 
are nucleated by members of the intra-
cellular nucleotide-binding domain and 
leucine-rich repeat containing (NLR) 
receptor family as well. The NLRP1b 
inflammasome is activated by Bacillus 
anthracis lethal toxin, whereas flagellin 
and type III secretion systems (T3SS) 
of virulent bacterial pathogens such as 
Salmonella enterica and Pseudomonas 
aeruginosa trigger the NLRC4 inflam-
masome. Each of these inflammasomes 
has been implicated in human diseases, 
but the NLRP3 inflammasome re-
sponds to the broadest array of medically 
relevant pathogen-associated molecular 
patterns (PAMPs), damage-associated 
molecular patterns (DAMPs), and in-
sults. Indeed, DAMPs like extracellu-
lar ATP and hyaluronic acid, medically 
relevant crystals such as alum, CCPD, 
MSU, silica, and asbestos, ionophores 
such as nigericin, and β-fibrils such as β- 
amyloid can all engage the NLRP3 in-
flammasome (see figure). Moreover, the 
major component of the outer mem-
brane of Gram-negative bacteria, LPS, 
activates NLRP3 through a noncanon-
ical pathway involving caspase-11. The 
inflammasome adaptor apoptosis-asso-
ciated speck-like protein containing a 
CARD (ASC) connects sensor com-
ponents within the inflammasome to 
caspase-1 and is observed in a microme-
ter-sized supramolecular fibril structure 
in the stimulated cell named the “ASC 
speck.” Caspase-1 proteolytically ma-
tures IL-1β and IL-18, two highly po-
tent inflammatory cytokines that also 
act as co-stimulators of T cell functions 
(Dinarello, 2009). Caspase-1 and the 
related inflammatory caspases 4, 5, and 
11 also cleave gasdermin D to induce 
pyroptosis, which is a proinflammatory 
form of regulated necrosis that is intrin-
sically associated with the passive release 
of IL-1β and IL-18 into the extracellular 
milieu along with DAMPs such as IL-
1α, HMGB1, and ATP (Kayagaki et al., 
2011; Shi et al., 2014).
Insight into the signaling mecha-
nisms by which inflammasomes respond 
to particular DAMPs and PAMPs offers 
new entry points to block caspase-1 
activation with more precision. Given 
its role in driving caspase-1 activation 
in the context of diverse pathological 
conditions, the NLRP3 inflammasome 
is increasingly regarded as an attractive 
target for reducing destructive inflam-
mation in autoinflammatory, rheumatic, 
metabolic, cardiovascular, and neurode-
generative diseases. In this issue, Jiang et 
al. identify CY-09 as a novel inhibitor 
of the NLRP3 inflammasome that acts 
as a competitive inhibitor of nucleotide 
binding to the central NLRP3 NAC 
HT domain. Binding of ATP/dATP to 
NLRP3 was shown previously to be 
required for NLRP3-dependent IL-1β 
secretion (Duncan et al., 2007). Several 
compounds that interfere with the in-
trinsic ATPase activity of NLRP3 have 
been reported (Juliana et al., 2010; He 
et al., 2014), but they target additional 
proteins with roles in innate immunity, 
suggesting that their selectivity profile 
would need significant optimization 
before widespread adoption as inflam-
masome-targeting agents. In contrast, 
Jiang et al. (2017) show that CY-09, 
unlike the closely related compound 
cystic fibrosis transmembrane receptor 
(CFTR)inh-172, inhibits neither CFTR 
gating nor TLR signaling. Moreover, 
micromolar concentrations of CY-09 
selectively inhibited the NLRP3 inflam-
masome without impeding caspase-1 
activation by the NLRC4 and AIM2 
inflammasomes (Jiang et al., 2017). It 
would be interesting to analyze CY-09 
against the NLRP1b and Pyrin inflam-
masomes to further narrow down its in-
flammasome selectivity profile.
The NLRP3 inflammasome 
uniquely requires a two-step mechanism 
for activation: transcriptional up-reg-
ulation of NLRP3 and pro-IL-1β, for 
example by TLR signaling, serves as a 
priming step for subsequent activation 
by NLRP3 agonists (Bauernfeind et al., 
2009). Importantly, CY-09 did not in-
terfere with TLR4 priming, but instead 
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blocked NLRP3 oligomerization and 
ASC recruitment in the activation step 
(Jiang et al., 2017). Glyburide was the 
first compound shown to selectively 
inhibit PAMP-, DAMP-, and crystal- 
induced activation of the NLRP3 in-
flammasome without interfering with 
other inflammasome pathways (Lam-
kanfi et al., 2009). Currently, MCC950/
CRID3 and related diarylsulfonylurea 
compounds that are structurally re-
lated to glyburide are the most potent 
reported inhibitors of the NLRP3 in-
flammasome with IC50 values around 20 
nM (Perregaux et al., 2001; Coll et al., 
2015; Primiano et al., 2016). MCC950/
CRID3 was shown to block activa-
tion of the NLRP3 inflammasome in 
ex vivo–stimulated murine and human 
macrophages and monocytes. However, 
unlike for CY-09, the molecular target 
and mechanism by which MCC950/
CRID3 and related sulfonylurea mole-
cules inhibit the NLRP3 inflammasome 
remains enigmatic.
Jiang et al. (2017) also showed that 
CY-09 can be used for limiting NLRP3 
inflammasome activation in vivo. CY-09 
showed favorable in vivo and ex vivo 
pharmacokinetic properties for stability, 
safety, and oral bioavailability, resembling 
those of MCC950/CRID3 (Coll et al., 
2015; Primiano et al., 2016; Jiang et al., 
2017). MCC950/CRID3 was shown to 
inhibit NLRP3-dependent pathology 
in preclinical disease models, including 
the Nlrp3Ala350Val-neoR knock-in mouse 
model of CAPS (cryopyrin-associated 
autoinflammatory syndromes), the ex-
perimental autoimmune encephalomy-
elitis mouse model of multiple sclerosis, 
the imiquimod cream–induced mouse 
model of skin inflammation, and house 
dust mite–induced acute airway inflam-
mation in mice (Coll et al., 2015; Primi-
ano et al., 2016). CY-09 also prevented 
neonatal lethality in the Nlrp3Ala350Val-neoR 
knock-in mouse model of CAPS, it im-
proved diabetic symptoms in mice given 
a high-fat diet and blocked NLRP3- 
dependent caspase-1 activation and IL-1β 
secretion from human peripheral blood 
mononuclear cells (PBMCs) of healthy 
donors and synovial fluid cells of gouty 
arthritis patients (Jiang et al., 2017).
The findings presented by Jiang et 
al. (2017) suggest that further develop-
ment of CY-09 might provide a novel 
avenue toward therapeutic inhibition 
of the NLRP3 inflammasome. IL-1 
blocking biologics have demonstrated 
clinical efficacy in rheumatic diseases 
(gout, pseudogout, systemic juvenile 
idiopathic arthritis, and Still’s disease) 
and rare hereditary monogenetic au-
toinflammatory diseases such as CAPS 
and familial Mediterranean fever. In ad-
dition, a recent study found that IL-1β 
inhibition significantly reduced the risk 
for stroke and cardiovascular events in 
coronary artery disease patients with 
inflammatory atherosclerosis (Ridker 
et al., 2017a). The IL-1β–targeting 
therapy also appeared to protect these 
patients from lung cancer and lung can-
cer–associated mortality (Ridker et al., 
2017b). However, as with other cyto-
kine-blocking therapies, IL-1β neutral-
ization comes with an increased risk 
for serious life-threatening infections 
and sepsis. Therapies acting upstream 
of IL-1β secretion and targeting select 
inflammasome complexes have the po-
tential for improved safety because the 
nontargeted inflammasomes should still 
mediate immune defense when the pa-
tient faces an acute infection. Selective 
inflammasome targeting could also have 
increased therapeutic potency through 
the simultaneous blockade of IL-1β, IL-
18, and pyroptosis. A major task ahead 
is to develop more potent CY-09 ana-
logues that target the NLRP3 inflam-
masome in the low nanomolar range 
IC50 values noted for MCC950/CRID3. 
Historically, generating selective inhibi-
tors of ATP-binding pockets has been 
Activation of the NLRP3 inflammasome and its inhibition by CY-09 and sulfonylurea 
compounds. Activation of the NLRP3 inflammasome involves two steps. First, TLR4 
stimulation induces transcriptional up-regulation of NLRP3 and the inflammasome 
substrate proIL-1β. In the second activation step, NLRP3 agonists such as ATP, the 
ionophore nigericin, pore-forming toxins and internalized crystals, and β-fibrils trigger 
NLRP3 oligomerization, ASC speck formation, and inflammasome-mediated caspase-1 
autoactivation. Caspase-1 cleaves its cytokine substrates IL-1β and IL-18, and it induces 
pyroptosis through cleavage of gasdermin D, which promotes the passive release of 
IL-1β and IL-18 along with DAMPs such as IL-1α and HMGB1. CY-09 inhibits NLRP3 
inflammasome assembly by blocking ATP/dATP binding in the central NAC HT domain, 
whereas the target and mechanism of action of sulfonylurea compound MCC950/CRID3 
are unknown.
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challenging. Therefore, it would also be 
critical to profile any CY-09 analogues 
for cross-reactivity against the enzy-
matic activity of a broad panel of protein 
kinases and ATPases. Nevertheless, it is a 
goal worth pursuing given the tremen-
dous benefits selective inflammasome 
inhibition might offer to patients.
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